Deal-Making
thumbnail
Deal-Making
J&J expands immunotherapy portfolio with $850m Proteologix buyJ&J expands immunotherapy portfolio with $850m Proteologix buy
Johnson & Johnson (J&J) will acquire bispecific antibody developer Proteologix for $850 million in cash and additional milestone payments.
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.